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Abstract
Objective: Assess the efficacy of a nestorone plus testosterone gel at suppressing progestin
levels and spermatogenesis.
Design: Systematic literature review.
Methods: Searches were done in PubMed and Dartmouth library using the terms nestorone,
randomized control trial, human, and male. Limits used while searching included published in
the last 10 years, randomized control trials, and English.
Results: Using the search criteria, the following three studies were found that met the
inclusion/exclusion criteria of this study: Ilani et al, Zitzmann et al, and Anawalt et al. All three
studies were found on PubMed and reference the Ilani et al study.
Conclusion: Nestorone plus testosterone gel is effective at suppressing progestin levels in the
short-term and spermatogenesis over the course of several weeks. This drug has an efficacy
similar to female oral contraceptives and a better efficacy than any existing non-invasive male
contraceptive. The effective dose, level of compliance, and long-term side effects require further
study.

Introduction
Since 1960, the burden of using a reliable hormone-based contraceptive has been on
the female partner in a heterosexual relationship. While condoms have been around since the
17th century, there has never been a reliable and reversible male pharmacological or hormonal
contraceptive. Even so, the failure rate with modern condoms is still 13%, making their
effectiveness much less than female hormonal contraceptives.1 While vasectomies have a near
100% success rate and are somewhat reversible2, only 2.4% of men worldwide choose this
option.3 The negative stigma and various misconceptions about vasectomies have contributed
to their lack of popularity.
Nestorone (segesterone acetate) is a transdermal synthetic progestin gel which has
been studied as a possible method of contraception since 1995.4 In 2018, the FDA approved its
contraceptive use as a vaginal ring when combined with ethinyl estradiol, under the trade name
Annovera.5 Currently, Nestorone has only been tested in stage II clinical trials as a male
contraceptive, but there are still ongoing clinical trials that are evaluating its efficacy.
From what is known about Nestorone and its possible efficacy as a male contraceptive,
it has little to no androgenic, estrogenic, or glucocorticoid activity.6 Nestorone is thought to

inhibit gonadotropins by a mechanism other than acting on androgen receptors, directly
inhibiting testosterone production.7 To decrease the possible negative androgen effects that
Nestorone may have, it has always been co-administered with transdermal testosterone.8 An
oral formulation of Nestorone was tested during its early development, but due to its poor GI
absorption, decreased oral half-life, and lack of availability of an oral testosterone, transdermal
administration has been accepted as the preferred route of administration.7
In analyzing the development of a hormonal male contraceptive, the main factors to look
at are efficacy, ease of use, long-term compliance, and the minimization of adverse effects. This
study analyzes three double-blinded randomized controlled trials which all used a combination
Nestorone and testosterone transdermal gel to provide adequate gonadotropin suppression and
prevention of pregnancy.

Methods
An initial search of PubMed and Dartmouth library was performed in September 2020
using the terms nestorone, randomized controlled trial, human, and male. Limits included
“published in the last 10 years, randomized controlled trials, English.” This yielded 6 articles.
Three articles were chosen based on their similar research methods and purposes. A search of
the Cochrane Library and JMU Database failed to identify additional studies.

Results
Study #1
A New Combination of Testosterone and Nestorone Transdermal Gels for Male Hormonal
Contraception. Ilani et al.7
Objective: To compare and determine the effectiveness of a testosterone-based gel and a
combination testosterone plus nestorone gel with regards to suppressing spermatogenesis.
Table 1. Patient Inclusion Criteria
Male sex
Between 18 and 50 years old
No chronic illness
Normal physical exam, blood chemistries,
and no evidence of a urinary tract infection
Two consecutive sperm concentrations of at
least 15 million/ml

Study Design
This was a randomized, double-blind, clinical trial consisting of 99 males, conducted at
two different academic medical centers. Table 1 outlines the inclusion criteria.
Initially, 210 men were screened for the study, eventually leading to 99 participants.
Reasons that screened individuals were not included in the study include: withdrawal of
consent, low sperm count, substance abuse, abnormal chemistries, high BMI, high blood
pressure, abnormal history and physical exam, and being lost to follow-up. The 99 study
participants were randomized into three different groups and applied the trial drug daily for a
period of 24 weeks. Group one self-administered a combination of 10 mg testosterone plus
placebo gel. Group two self-administered a combination of 10 mg testosterone plus 8 mg
nestorone gel. Group three self-administered a combination of 10 mg testosterone plus 12 mg
nestorone gel. After the treatment period, the subjects were followed for a minimum of 12 weeks
or until two consecutive semen samples had a sperm concentration of at least 15 million/ml.
This concentration of sperm was observed in a previous study to serve at the baseline level for
normal minimum sperm concentration.
Throughout the study, participants were required to use a secondary form of
contraception, if engaging in sexual activities with their partner. Participants had serum
concentrations of testosterone, free testosterone, nestorone, LH, FSH, Hgb, and semen
concentrations obtained at regular intervals throughout the trial. In addition, other baseline labs
included complete blood count, complete metabolic panel, lipid panel, and prostate specific
antigen.
The goal of the study was to demonstrate the suppression of spermatogenesis to a level
of no more than 1 million/ml by 20 weeks of daily use. The suppression of sperm concentration
to less than this amount is considered by the study to be the cutoff for contraceptive efficacy
and is comparable in efficacy to female oral contraceptive medications.
All semen analyses were performed by trained technologists using the standard
techniques outlined in the World Health Organization Laboratory Manual for the Examination of
Human Sperm.
Study Results
Of the 99 initial participants, 62 completed the study until at least week 20, with a near
equal distribution of participants in each of the three study groups. Six additional participants
who continued the trial through week 20 were later excluded due to nonadherence to the
medication regimen. Data analysis was performed on the remaining 56 participants, per
protocol.
There was a significantly higher percentage of participants who had a sperm
concentration of 1 million/ml or less with the groups that used nestorone gel. Group one, who
used testosterone plus placebo gel, only had 23% of participants achieve a sperm concentration
of less than 1 million/ml, whereas groups two (testosterone plus nestorone 8mg) and three
(testosterone plus nestorone 12mg) saw a suppression of 89% and 88%, respectively.
Serums testosterone and free testosterone levels saw no significant change throughout
the trial in any group, but serum LH and FSH were significantly more suppressed in the groups
receiving nestorone gel compared with the testosterone plus placebo group.

Participants in all groups had no significant changes in sexual desire, sexual activity,
sexual enjoyment, satisfaction with erections, and fullness of erections when compared to
baseline.
There were no serious adverse events leading to participants discontinuing the trial.
Most participants that failed to complete the trail stated their reason as inconvenience of study
visits or failure to come for follow-up visits. The most frequent side effects were acne (21%) and
insomnia (6%) with no difference between treatment groups.
Study Critique
The lack of a pharmacologic “gold standard” for male contraception makes analysis of
any male contraceptive trial difficult. The study’s already small sample size (n=99) was further
decreased to 56 participants after many failed to complete the trial period or completed the
study but ended up being noncompliant with the medication. The study was successfully able to
identify at least one participant that lied about their compliance, decreasing the likelihood of
erroneous data. Though this discontinuation rate seems high, it is much less than the
discontinuation rate of female contraceptive trials, which ranges from 32-49%. Furthermore, the
study does suffer from only having healthy participants so extrapolation to a larger population is
difficult.
Having multiple study locations and a standard for the analysis of sperm both likely
helped to decrease any bias and increase the uniformity of the data. By choosing to have the
study performed at academic hospitals, there was likely a diverse patient pool to choose
participants from.
One downside to a nestorone gel contraceptive is that complete suppression of
spermatogenesis has not been achievable to date.
Study #2
Impact of Various Progestins With or Without Transdermal Testosterone on Gonadotropin
Levels for Non-invasive Hormonal Male Contraception: A Randomized Clinical Trial. Zitzmann
et al.9
Objective
To evaluate and compare the effect of different oral or transdermal progestins on the
suppression of both follicle stimulating hormone (FSH) and luteinizing hormone (LH) in healthy
men.
Table 2. Patient Inclusion Criteria
Male sex
Between 18 and 50 years old
Normal mental and physical health
BMI between 18 and 33 kg/m2

Normal FSH, LH, Testosterone, and Sperm counts according to WHO Guideline

Study Design
Fifty-six healthy Caucasian males that responded to a press advertisement were
selected to participate in a randomized control trial. Table 2 outlines the inclusion criteria for this
study. Each participant was placed into one of eight different treatment groups. This study used
the following four progestins; cyproterone acetate (CPA), nestorone (NES), norethisterone
acetate (NETA), and levonorgestrel (LNG). Each progestin was then further split into two
different groups with differing dose amounts. Each treatment group underwent two phases. The
first phase (two weeks) consisted of only the respective progestins being administered. The
second phase (four weeks), 50 mg/day of transdermal testosterone gel was administered in
combination with each respective progestin. The purpose of adding transdermal testosterone
was to evaluate if testosterone could be added to provide normal androgenic function in men,
while maintaining suppression of gonadotropin. After the four weeks of phase two, all
participants completed a wash out period for three weeks. The study design is outlined in Table
3.
Each participant was instructed to take their respective progestin and record it in a drug
diary, as well as keeping all drug containers. CPA, NETA, and LNG were all administered orally.
The participants in the NES study groups all received 1 g of gel per day, containing either 2 mg
of NES or 3 mg of NES, depending on their respective study group. Transdermal testosterone
was administered through a 5g gel containing 50 mg of testosterone, that subjects applied each
morning. This level of testosterone has been proven to provide serum testosterone
concentrations within the normal level for one day.
Serum concentrations of FSH, LH and testosterone were all measured at weeks 0,
2,3,4,5,6,7,8, and 9. Target FSH and LH concentrations were both 0.5 IU/mL, a level that is
consistent with spermatogenesis suppression. Additional safety parameters, resting blood
pressure and heart rate, hematocrit, prostate specific antigen (PSA), insulin sensitivity, highresolution C-reactive protein (hsCRP), and a lipid panel, were all collected at week 0,2,6, and
after the three week washout period. All venous blood samples were collected after overnight
fasting between 0800 and 1200 hours. While semen analysis was not the main purpose of this
study, spermatozoa concentrations were measured at week 0, 6, and at the end of the washout
period. Semen analysis was conducted in accordance with WHO standards.

Table 3. Study Design
Group

Progestin

Dose

Route

n

1

Cyproterone
Acetate

10 mg/day

Oral

7

2

Cyproterone
Acetate

20 mg/day

Oral

7

3

Nestorone

2 mg/day

Transdermal

7

4

Nestorone

3 mg/day

Transdermal

7

5

Norethisterone
Acetate

5 mg/day

Oral

7

6

Norethisterone
Acetate

10 mg/day

Oral

7

7

Levonorgestrel

120 µg/day

Oral

7

8

Levonorgestrel

240 µg/day

Oral

7

Study Results
Protocol compliance was measured by reviewing participants’ drug dairies and counting
empty study drug containers. Compliance was estimated to be over 95%. After the first phase
(week 2), CPA was the only progestin that suppressed FSH and LH below 0.5 IU/mL. However,
at the end of phase two (week 6) all trial groups, with the exception of NES 2 mg, suppressed
FSH and LH below 0.5 IU/mL. Regarding the safety parameters measures, testosterone,
hemoglobin, hematocrit, and insulin sensitivity all decreased markedly during the first phase.
However, during the second phase and the addition of testosterone, all of these safety
parameters increased to normal levels. The remaining safety parameters did not change
throughout the study. There were no serious adverse events reported. The most common
adverse events were 3 participants experiencing night sweats and 2 participants experiencing
libido. Three participants dropped out of the study, however none were because of adverse
events.
Study Critique
Strengths of this study include using a randomized control trial, using multiple doses of
the same drug to determine appropriate dosages, having a period with progestins only to see
the effects on no testosterone, and having no serious adverse events.
The biggest shortcoming of this study was the relatively small sample size of fifty-six,
and the short six week time frame of the study. A further study, with a larger sample size and a
longer study period, would be needed to fully understand the benefits and side effects of these

drugs. Larger sample sizes would also help to negate any interindividual transdermal absorption
of NES or testosterone.
While this study was a randomized control trial, it was not blind. While the participants
who knew what drug they were receiving most likely did not affect their FSH and LH
concentrations, having a blind trial would help minimize any potential confounding variables.
This study also did not use sperm concentrations as a marker for effective contraception. They
used FSH and LH levels that have a correlation to sperm concentrations, however, FSH and LH
levels are a surrogate outcome.
Lastly, the drugs used in this study were all provided by Bayer-Schering Pharma. While
many companies make these different progestins, having the drugs provided by a
pharmaceutical company raises the concern for a possible conflict of interest.
Study #3
Combined nestorone-testosterone gel suppresses serum gonadotropins to concentrations
associated with effective hormonal contraception in men. Anawalt et al.10
Objective: Compare and determine the effectiveness of a testosterone-based gel and a
combination testosterone plus nestorone gel with regards to suppressing serum LH and FSH
concentrations.
Study Design
This was a randomized, double-blind, clinical trial consisting of 44 males, conducted at
two different research institutions in Los Angeles, CA and Seattle, WA. Table 4 outlines the
inclusion criteria.
Table 4. Patient Inclusion Criteria
Male sex
Between 18 and 50 years old
No chronic illness
Normal physical exam, blood chemistries,
and no evidence of a urinary tract infection
No use of anabolic steroids within 3 months
No moderate/severe depression (determined
using the PHQ-9)
Sperm concentration of at least 15 million/ml
Initially, 88 men were screened for the study, eventually leading to 44 participants. The
44 study participants were randomized into two different groups and applied the trial drug daily
for a period of 28 days. Group one self-administered a 62.7 mg testosterone gel. Group two
self-administered a combination of 62.5 mg testosterone plus 8.3 mg nestorone gel (NES+T).

After the treatment period, the subjects were followed for an additional 28 days which was
considered a “washout period”. This occurred when serum testosterone, gonadotropin
concentrations, complete blood count, complete metabolic panel results, and semen
concentration returned to baseline or were within the normal ranges. The medication was
provided in prefilled syringes and applied daily to the shoulders. Participants returned to the
research center on a predetermined schedule seven times during the trial period.
Throughout the study, participants were asked to have any female sexual partner use a
secondary form of contraception, if engaging in sexual activity. Participants had serum
concentrations of testosterone, free testosterone, nestorone, LH, FSH, Hgb, and semen
concentrations obtained at regular intervals throughout the trial. In addition, other baseline labs
included complete blood count, complete metabolic panel, and prostate specific antigen.
The goal of the study was to demonstrate the suppression of LH and FSH to a level of
no more than 1.0 IU/L by 28 days of daily use. The suppression of LH and FSH to this level is
associated with the suppression of sperm concentrations to less than 1 million/ml, the level at
which a medication can be declared an effective form of contraception.10
All hormone measurements and analyses were performed by trained technologists using
previously validated and reported assays. Study analysis was performed per protocol.
Study Results
Of the 44 men who started the study, 4 participants withdrew early from the study. Two
participants reported scheduling conflicts, one withdrew due to possible side effects, and one
withdrew for personal reasons. Three men in the NES+T group were not included in the
analysis because of lack of meeting inclusion criteria, leaving 37 men available for analysis.
Participants in the NES+T study group report reported 89% everyday compliance.
Serum FSH and LH concentration in the NES+T group were significantly suppressed by
day 7 and remained there throughout the entirety of the treatment period. By the fourth week,
84% of the NES+T group had FSH and LH concentrations below 1.0 IU/L, while only 16.7% of
the testosterone only group had FSH and LH concentrations below 1.0 IU/L. By day 31, 3 days
after stopping treatment, serum gonadotropins were not significantly suppressed. By day 56, 28
days after stopping treatment, serum gonadotropins were at baseline concentrations.
Nestorone serum concentration continued to rise throughout the treatment timeframe for
the NES+T study group. After the 28-day treatment time frame, nestorone remained
measurable for 72 hours and by day 56 was completely unmeasurable.
Sperm concentrations were measured at baseline and then on day 28 of treatment. The
sperm concentration of the testosterone only group remained largely unchanged by day 28 with
a level of 85 +/- 72 million/mL. The NES+T group’s sperm concentration decreased from 69
million/mL to 40+/- 43 million/mL. This is much lower concentration than the testosterone group
but is still not at the <1 million/mL that is associated with effective contraception.
There were no serious adverse events leading to participants dropping out of the study.
One participant in the testosterone only group reported decreased libido that could possibly be a
result of the study. One participant in the NES+T group reported a sunburn over the site of gel
application, and another reported a rash over the site of gel application, both which could
possibly be related to the study. There was no change in any of the safety parameters being

measured. None of the participants reported any changes in psychosexual changes 1 weeks
after treatment was stopped.
Study Critique
The study’s already small sample size (n=44) was further decreased to 37 participants
after many failed to complete the trial period or did but ended up being noncompliant with the
medication. This study is very similar to the first study, where the study does suffer from only
having healthy participants, so extrapolation to a larger population is difficult.
Strengths of this study include using a randomized control trial and having no serious
adverse events.
One limitation of this study is that all doses of the trial medications were measured and
placed into pre-filled syringes by pharmacists. It is unlikely that a consumer would be as precise
with their dosages unless the administration method can be refined. Also, the length of the study
was too short to measure the effectiveness at inhibiting spermatogenesis.
The efficacy of a gel as the route of administration must also be questioned. The trial did
not take into account the effectiveness of the drug if it was washed or rubbed off after a certain
period of time.

Discussion
Table 5. Study Comparison
Ilani et al

Zitzmann et al

Anawalt et al

Participants, N

99

56

44

Population

Healthy males age
18-50

Healthy males age
18-50

Healthy males age
18-50

Study Length

24 weeks

6 weeks

4 weeks

Primary Interest

Compare
effectiveness of
testosterone vs
testosterone + NES
in suppressing
spermatogenesis

Compare
effectiveness of 4
types of progestins in
suppressing
spermatogenesis

Compare the
effectiveness of
testosterone vs
testosterone + NES
in suppressing
spermatogenesis

Measurement of
Efficacy

Sperm count < 1
million/ mL

Serum FSH and LH
concentration < 0.5
IU/mL

Serum FSH and LH
concentration < 1
IU/L

Pharmacologic contraception is still something that does not exist for the male
population. Men have to either rely on barriers, spermicide, other nonpharmacologic methods of
birth control or solely trust female contraception. These three novel trials were the first three

trials that showed efficacy in either the suppression of spermatogenesis or the decrease in
levels of FSH and LH.
Due to the inability of testosterone to be absorbed enterally, these trials focused on the
use of transdermal application. This both allowed for an increase in ease of application and the
achievement of a steady state level of distribution once the medication was absorbed into the
skin, all while remaining a non-invasive treatment.
An overview of the three studies is provided (Table 5). Due to its longer trial period, the
Ilani et al study was the only one that focused on the suppression of spermatogenesis as a
measurement of effectiveness. The other two trials, Zitzmann et al and Anawalt et al, used
serum FSH and LH concentrations as a surrogate outcome for spermatogenesis.
While both Ilani et al and Anawalt et al compared the effectiveness of using NES+T
versus only using testosterone for suppressing spermatogenesis, Zitzmann et al compared the
effectiveness of 4 novel progestins, with and without testosterone, at suppressing
spermatogenesis. For the purpose of this study, only the effectiveness of the nestorone group
was discussed.
None of the trials reported any serious adverse events, but two common complaints
observed were skin irritation, to include acne and sunburn, and a mild decrease in libido.
All three studies demonstrated the effectiveness of using NES gel at suppressing
spermatogenesis. Ilani et al demonstrated that using either 8 mg of NES+Tgel or 12 mg of
NES+T gel produced a sperm count < 1 million/mL for 89% and 88% of their respective study
participants. Similarly, Anawalt et al found that using 8.3 mg NES +T gel suppressed serum
FSH and LH to a concentration <1 IU/L in 84% of their study participants. Both Ilani et al and
Anawalt et al used a control group that tested the effectiveness of testosterone only at
suppressing spermatogenesis. Ilani et al demonstrated that only 23% of the participants
administering testosterone only reached a sperm count of <1 million/mL and Anawalt et al
demonstrated that only 16.7% of participants reached a FSH and LH concentration <1 IU/L. In
comparison, Zitzmann et al tested the effectiveness of using 2 mg of NES and 3 mg NES, and
found that on average all of the participants of the NES 3 mg group achieved a serum FSH and
LH concentration <0.5 IU/mL, while on average none of the NES 2 mg group did. It is interesting
to note that Zitzmann et al and Anawalt et al used different cutoff values for serum FSH and LH
concentrations that correlate with adequate spermatogenesis. Both studies cite different
sources for how they determine their respective cutoff values, but the cutoff value that Zitzmann
et al used is 500 times higher than the cutoff value that Anawalt et al used.
Similar to female contraceptive trials, non-adherence remains an issue that plagues the
effectiveness of medications. Each of the studies reported a compliance between 88 and 95%.
This lack of complete compliance can result in a lower spermatogenesis rate, decreased
suppression of progestins, and result in sperm rebound between periods of suppression. This
failure to comply with a treatment regimen also translates to current accepted standards of
contraception. Even though oral contraceptives have proven their high level of efficacy over the
years, their levels of discontinuation over six months are 31% and 69%, respectively.7

Conclusion
Nestorone plus testosterone as a transdermal gel has shown promise in both
spermatogenesis suppression and the decrease of progestins to levels reflective of a future
decrease in spermatogenesis. All three trials used varying dosages of NES+T in an attempt to
find the optimal dosage. The Ilani et al and the Anawalt et al trial both included a dosage of 8
mg NES which seems to be at or near the optimal dosage of NES. Further trials should be done
to see if a dosage between 8 mg NES and 3 mg NES, the dosage used in the Zitzmann et al
trial, would be the optimal dose. The lower dose of NES used in the Zitzmann et al trial was
associated with less side effects but noted an ineffective level of progestin suppression.
Compliance with this medication remains one of the major issues with a male
contraceptive. By combining the nestorone and testosterone gels into single use packets,
application of the medication is simplified, potentially helping with compliance, acceptability, and
overall effectiveness in the suppression of progestins and spermatogenesis. Patients must be
educated on the transdermal application of this gel, as studies have shown that washing the
application site will significantly affect the level of absorption if within a few hours of placement.9
The majority of men in these studies were satisfied with the NES+T gel as a method of
contraception, and around 50% said they would use this as a primary method of contraception,
if available. These studies support the development of NES+T as a suitable male contraceptive
but require a longer trial period to further demonstrate the suppression of spermatogenesis.
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